Rivus Pharmaceuticals

Rivus Pharmaceuticals, Inc. is a company based in Charlottesville, Virginia, specializing in the development of innovative pharmaceutical solutions. With a team of 19 employees, Rivus Pharmaceuticals is focused on advancing the treatment of cardio-metabolic diseases. The company's core focus is on developing a new class of oral, once-daily, small molecule therapeutics known as Controlled Metabolic Accelerators (CMAs). These CMAs are designed to improve cellular metabolism and target the root causes of prevalent metabolic and cardiovascular diseases. Rivus Pharmaceuticals aims to address conditions such as type 2 diabetes, severe hypertriglyceridemia (SHTG), non-alcoholic steatohepatitis (NASH), and cardiovascular diseases like heart failure with reduced ejection fraction (HFpEF). Rivus Pharmaceuticals distinguishes itself through its commitment to developing innovative therapies that address the underlying mechanisms of these complex diseases. The company's CMAs represent a potentially transformative approach to treating cardio-metabolic disorders, offering the possibility of improved patient outcomes. For further inquiries, please visit Rivus Pharmaceuticals' website at www.rivuspharma.com/.